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Abstract: Breast cancer prescreening is carried out prior to the gold standard screening using 
X-ray mammography and/or ultrasound. Prescreening is typically carried out using clinical 
breast examination (CBE) or self-breast examinations (SBEs). Since CBE and SBE have high 
false-positive rates, there is a need for a low-cost, noninvasive, non-radiative, and portable 
imaging modality that can be used as a prescreening tool to complement CBE/SBE. This review 
focuses on the various hand-held optical imaging devices that have been developed and applied 
toward early-stage breast cancer detection or as a prescreening tool via phantom, in vivo, and 
breast cancer imaging studies. Apart from the various optical devices developed by different 
research groups, a wide-field fiber-free near-infrared optical scanner has been developed for 
transillumination-based breast imaging in our Optical Imaging Laboratory. Preliminary in vivo 
studies on normal breast tissues, with absorption-contrasted targets placed in the intramammary 
fold, detected targets as deep as 8.8 cm. Future work involves in vivo imaging studies on breast 
cancer subjects and comparison with the gold standard X-ray mammography approach.
Keywords: diffuse optical imaging, near-infrared, hand-held devices, breast cancer, prescreen-
ing, early detection
Introduction: breast cancer statistics
One in eight women in the USA is at the risk of developing breast cancer.1 In 2013, 
approximately 232,340 new cases of invasive breast cancer developed.1 Annually, 
1.3 million new cases of breast cancer are diagnosed worldwide,2 and 1.38 million 
new cases developed in 2011 worldwide.3 Half of the breast cancer cases occur in 
economically developing countries.3 Since 1990, death rates related to breast cancer 
have dropped by 34%.1 About 60% of breast cancer deaths occur in economically 
developing countries.3 Mortality has seen a decrease in developed countries due to 
earlier diagnosis and greater treatment options.2
American Cancer Society has set guidelines for detecting breast cancer in women 
aged 40 and older, which include an annual mammogram, an annual clinical breast exami-
nation (CBE), and an optional self-breast examination (SBE).1 Details of these various 
examinations are described in the “Different modalities used to image breast cancer” section. 
Prior to the description of the different examination or imaging tools used in breast cancer, 
the physiology and stages of breast cancer are described in the following section.
Breast cancer stages and imaging
The disease of breast cancer occurs when there are malignant cancer cells in the breast 
tissue.4 The causes of breast cancer are either external or internal. External causes 
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include tobacco, chemicals, radiation, and infectious 
organisms. Internal factors are mutations that are inherited 
as well as those that occur from metabolism, hormones, and 
immune conditions. Combinations of external and internal 
factors may lead to the initiation or promotion of breast can-
cer. It may take as long as 10 years of experiencing external 
factors before the cancer is detected.5
Stages of breast cancer
The different stages of detecting breast cancer are screening, 
diagnosis, and prognosis. Screening is performing exams 
on individuals who do not show symptoms of breast cancer 
in order to determine whether there is cancer. Screening 
helps to detect the cancer early before symptoms manifest 
and prior to spreading to other tissues. Common modali-
ties used in breast cancer screening are SBEs, CBE, and 
mammograms.
Having screened for breast cancer, further diagnostic 
tests are performed to confirm the disease and also to deter-
mine if the tumor(s) observed is benign or malignant. Being 
diagnosed with breast cancer, the patient then requires other 
tests to determine the prognosis and decide on treatment 
options. Some of these tests include estrogen and proges-
terone receptor test, human epidermal growth factor type 2 
receptor test, and multigene tests. Some of the imaging 
techniques used in the diagnostic stage are ultrasonography 
and magnetic resonance imaging (MRI).6 These tests give 
specific information to help identify the stage of the tumor 
and whether it is growing rapidly or slowly. Staging is then 
performed in order to classify the cancer into a stage rang-
ing from zero to four, with four being the most advanced. 
Some imaging modalities used throughout this stage are 
chest X-rays, computerized tomography (CT) scans, and 
bone scans.4
After being diagnosed, the patient may undergo neoad-
juvant therapy or primary therapy. Neoadjuvant therapy is 
a means to decrease tumor size if the tumor is too large to 
successfully remove. Primary therapy follows neoadjuvant 
therapy or may be the first step taken after diagnosis. It 
typically consists of surgery, more specifically mastectomies 
or lumpectomies, to remove the tumor. Following primary 
therapy, there is an adjuvant therapy which aims to prevent 
the recurrence of the cancer and promote longevity of the 
patient.7 Post-adjuvant therapy patients require periodic 
monitoring to ascertain that they are tumor free. The prog-
nostic stage is monitoring using imaging modalities that 
include mammograms, breast MRI, ultrasound (US), positron 
emission tomography (PET), and/or CT scans.8
Different modalities used  
to image breast cancer
The conventional prescreening/screening imaging modali-
ties, along with the emerging imaging modalities for breast 
cancer, are given in Table 1.9–48,50
SBe and CBe
Breast cancer prescreening is carried out prior to the gold 
standard screening using X-ray mammography and/or US. 
Prescreening is typically carried out using CBE or SBEs. 
CBE is carried out by the physician for early detection of 
skin irregularities9 or abnormalities in the breast tissue. Breast 
self-examination is carried out by women to increase public 
awareness and to become familiar with appearance and feel 
of their breasts.9,10 Approximately two thirds of women older 
than 40 years undergo periodic CBE. However, there exists 
minimal evidence to measure the effectiveness of CBE in 
detecting breast cancer. The advantage of SBE is that the 
patients can become familiar with their anatomy and perform 
the screening modality in a private setting at home. While 
CBE demonstrated a maximum sensitivity of 40%–69%, SBE 
had a low sensitivity of 12%–14%.32 Furthermore, it has been 
shown in randomized control trial that SBE has no positive 
effect compared to not performing it and that it actually leads 
to false positives. In general, both CBE and SBE have high 
false-positive rates and overdiagnose, that there is a need for 
an objective imaging modality at the prescreening stage.
X-ray mammography
Breast cancer screening involves screen-film and digital 
mammography, computer-aided detection, US, and MRI. 
Screen-film mammography involves using X-rays to obtain 
images that are captured on a film, while digital mammog-
raphy captures the X-rays through digital means which can 
then be read on a printed film or electronically on a computer. 
Digital mammograms are convenient to the radiologist inter-
preting the X-ray by allowing him/her to change the values 
of brightness, contrast, and magnification; however, they are 
at a greater price to the patients. Studies have demonstrated 
screen-film mammography to have a higher sensitivity than 
that of digital film mammography. Although computer-aided 
detection is supported by a small amount of data, it can locate 
lesions, such as calcifications, on mammograms, thereby 
increasing the amount of cancer detected as well as increas-
ing the accuracy of radiologists.11 In general, mammography 
reduces the risk of dying from breast cancer by 15%–20%, 
which can lead to a greater number of treatment options.9 
The advanced applications of digital mammography include 
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tomosynthesis and contrast-enhanced digital mammography. 
In tomosynthesis, multiple digital X-ray images are obtained 
at multiple angles of the X-ray tube in order to yield 3D 
images or individual slices in dynamic cine.12–14 In contrast-
enhanced digital mammography, a contrast agent (generally 
iodine based) is injected intravenously, and multiple X-ray 
images are obtained with a high contrast-to-noise ratio, which 
in turn reduce the visibility of microcalcifications.15,16
Magnetic resonance imaging
Not commonly used for screening but more so for diagnosing, 
MRI uses a combination of a magnetic field, radio waves, and 
computer processing in order to create images. Occasionally, 
it is used for screening young women with known increased 
risk of breast cancer due to gene mutations when mammo-
grams are not ideal. A study has also shown that using MRI in 
the screening stage leads to unnecessary biopsies and further 
examinations when compared to mammography screening.11 
The disadvantages of using MRI is its high cost of about ten 
times the cost of a mammogram, its low specificity relative to 
mammograms, the need for contrast agents (in some cases), 
and the long amount of time required to image a patient, 
especially exacerbated by a patient with low tolerance to 
enclosed spaces.11 The advanced applications of MRI for 
breast cancer imaging include diffusion and perfusion imag-
ing, proton magnetic resonance spectroscopy (MRS), and MR 
elastography. While the diffusion perfusion imaging offers 
information related to tissue microstructure from focusing on 
water protons, perfusion imaging follows the flow of blood 
to show the microvasculature.17 Proton MRS measures the 
resonance of protons to provide a spectrum in order to identify 
choline, a biomarker for cancer. In MR elastography, elec-
tromechanical drivers vibrate the breast to generate acoustic 
shear waves that are further imaged by MRI.12
Ultrasounds
USs have recently been approved by the Food and Drug 
Administration to aid in screening of breast cancer in patients 
with dense breast tissue, apart from its application as a 
diagnostic imaging tool. US employs sound waves to create 
images of the tissue features.18 The advantages of US are that 
it can differentiate benign and malignant masses as well as 
cysts and solid masses. The main drawback is that its effec-
tiveness varies depending on the skill of the US technician. 
US also has a greater amount of false positives compared to 
mammography, up to 12.9% compared to 6%, respectively.11 
In the clinic, the most common mode of US imaging is to 
obtain 2D images from B-mode scanning. In certain cases, 
compound imaging is carried out by combining multiple 
US images into one. Although compound imaging is better 
in quality than B-mode imaging, it suppresses the shadows 
that can be used to determine malignancy.12 On the other 
hand, Doppler US uses the Doppler effect to track blood 
flow in order to find malignant tumors through their neoan-
giogenesis.19,20 The advanced applications of US imaging 
at preclinical stage include sonoelastography (SE), tissue 
harmonic imaging, and US spiral computed tomography. 
While in SE, US images of the breast are obtained during its 
displacement, frequencies are filtered appropriately in tissue 
harmonic imaging in order to improve the contrast. US spiral 
CT is a combination of US and CT imaging used to obtain 
volumetric 3D images of the breast, although it can miss 
tumors located proximal to the chest wall.21
Nuclear imaging
Nuclear imaging yields functional images based on molecu-
lar properties, unlike the anatomical images as in X-ray, 
US, and MRI. Also, this technique involves radiation and 
is expensive, requires little or no breast compression, and 
shows promise in detecting cancer, especially in high-risk 
patients.12 In radio-immunoscintigraphy, tumor-associated 
antigens are targeted by an injected radiopharmaceutical 
agent, with antigen expression differing between normal 
and cancer cells. Scintimammography (SMM) is an imaging 
technique used in the diagnostic phase. It uses nonspecific 
radionuclides to identify malignant lesions. Usually, it follows 
a mammogram and identifies the lesions found in the mam-
mogram. It is also a useful postprimary and post-adjuvant 
therapy because it identifies tumor changes and recurrence 
as well as necrosis in the specific area.22 SMM has higher 
specificity than MRI, which makes it clinically applicable to 
detect lesions larger than 1 cm in diameter. PET, generally 
using 18F-fluorodeoxyglucose, uses glucose metabolism to 
detect cancer, especially in detection of malignancies and 
metastatic disease in solid organ tumors.12 The advanced 
applications of nuclear breast imaging include positron emis-
sion mammography (PEM) and PET/CT. PEM focuses on 
imaging only the breast tissues unlike the entire body as in 
PET imaging, and serves as the best screening tool in high-
risk patients.23 PET/CT is a multimodal imaging approach 
that combines PET (for functional information) and CT (for 
anatomical information).24
emerging modalities (experimental stage)
Some of the emerging technologies for breast cancer imag-
ing include thermography, microwave imaging, electrical 
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impedance imaging spectroscopy (EIS), Raman spectroscopy, 
and diffuse optical imaging (DOI).
Thermography is another imaging technique used in 
the diagnostic phase. It identifies vascular and temperature 
changes noninvasively and without radiation.25 A study per-
formed by Sterns et al has proven this modality to result in a 
large amount of false positives and false negatives. The study 
also reported inconsistent interpretation of the thermograph.26 
Another study states thermograph findings to be more evi-
dent of the metabolic rate and expansion state as opposed 
to its actual size and depth. The advantage of demonstrating 
metabolic and growth rate is that a prediction can be made 
that determines risk of the patient. For instance, one study 
reports that 38% of false-positive patients develop breast 
cancer within 4 years.10
EIS is also used in the diagnostic phase of breast cancer. 
This modality measures local dielectric properties of cancer 
cells, including electrical conductance and capacitance. This 
is performed by applying current to the patient with varying 
frequency, current, flow, and voltage. The values gained from 
cancer cells are different than those of normal cells. A study 
performed by Malich et al shows a sensitivity of 80.5% and 
a specificity of 64.7%. The features in the patient’s anatomy, 
such as scars, hairs, and bone, can result in false positives. 
A high amount of false positives along with an effectiveness 
that varies with the conductor of the EIS results in limited 
clinical use.27 In a review article by Vreugdenburg et al, it was 
found that only one study used EIS for screening, whereas 
the other studies focused on women with already diagnosed 
breast cancer. The study focusing on screening did not use a 
valid reference test to ascertain if the patients were healthy 
or had cancer. The study did not recommend the use of EIS 
for screening due to lack of data regarding the ability of EIS 
to detect cancer in asymptomatic women.28
Microwave imaging employs microwave or millimeter 
waves to image dielectric bodies.29 This modality offers low 
contrast between healthy fibroglandular tissues, where the 
majority of breast tumors occur, and malignant tumors pose 
as a challenge for microwave imaging of the breast tissue. 
The challenges of high tissue attenuation resulting in limited 
depth of wave penetration, and loss of resolution with higher 
penetration depth limit its immediate clinical translation for 
breast cancer.
The various other emerging modalities (not described 
here) include DOI, Raman spectroscopy, diffraction 
techniques (eg, diffraction-enhanced imaging and small 
angle X-ray scattering), compression and palpation method 
(via piezoelectric sensing), X-ray diffraction of hair, breath 
detection using gas chromatography and mass spectroscopy, 
and canine scent detection.12
DOI: physics and breast  
cancer application
In the past three decades, DOI is emerging as a breast cancer 
imaging device with applicability at both diagnostic and 
prognostic stages of breast cancer imaging. DOI uses near-
infrared (NIR) light between 650 nm and 900 nm to image 
the differences in the blood oxygenations between the tumor 
and normal breast tissues. Based on the nature of the optical 
imaging instrument, its applicability for early-stage breast 
cancer detection is also attempted by various research groups, 
as described in the following sections.
Wavelengths of light from 650 nm to 900 nm are mini-
mally absorbed and preferentially scattered upon interaction 
with tissue allowing for deeper light penetration than possible 
at other optical wavelengths (Figure 1).51 The technology that 
uses light in this NIR wavelength region to noninvasively 
image deep tissues is called as NIR optical imaging (or DOI). 
The low absorption occurs due to the main absorbers in physi-
ological tissue, that is, water and oxy- and deoxy-hemoglobin, 
which absorb less light than at other optical wavelengths.52 
The difference in optical properties (ie, absorption and scat-
tering of the light) between normal and diseased tissues is 
used to characterize tissues and detect abnormalities.
Deeper tissue penetration allows optical imaging to be 
implemented as an imaging technology for breast cancer 
detection, diagnosis, and/or prognosis. Optical imaging 
provides a functional imaging approach with decent spatial 
resolution and contrast. Optical imaging also requires less 
imaging time compared to MRI, and is also less expensive. 
The combination of benefits offered by optical imaging in 
terms of less imaging time (,1 minute), good spatial and 
excellent temporal resolution, good contrast (from functional 
imaging), and relatively inexpensive instrumentation suggests 
that optical imaging is potentially an emerging technology for 
future clinical applications in the areas of breast cancer imag-
ing, brain mapping, and any noninvasive body tissue imaging. 
Additionally, the source powers employed during optical 
imaging are within the safe limits (typically ,50 mW), and 
NIR light is non-radiative in nature.
Optical imaging and breast cancer
Optical imaging has been utilized toward various aspects of 
clinical breast imaging: i) measurement of optical and physi-
ological properties of healthy breast tissue; ii) detecting the 
presence of abnormal tissue (ie, tumors); iii) distinguishing 
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between benign and malignant tumors; iv) monitoring 
response to neoadjuvant chemotherapy; v) sentinel lymph 
node mapping; and vi) tomographic imaging of the entire 
breast.54 These breast imaging applications in some cases 
involved the use of external fluorescent contrast agents to 
improve the optical contrast of the diseased regions from the 
normal breast tissue.55,56
Optical imaging uses NIR light as a continuous-wave 
(CW), frequency (frequency domain, FD), or pulse (time 
domain) signals. In CW imaging, the source light intensity 
remains constant in time and attenuates as it propagates through 
the tissue due to absorption and (indirectly) to scattering. FD 
imaging uses time-dependent intensity-modulated light that 
becomes attenuated and phase shifted as it propagates through 
the tissue. Time-domain imaging uses time-dependent (pico- 
or nanosecond) pulses of light that broaden and attenuate as 
it propagates through the tissue. Different types of optical 
devices developed for breast cancer detection employing 
one or more of these measurement techniques have been 
developed toward DOI of breast tissue. The most commonly 
employed sources in these devices include laser diodes and 
light-emitting diodes (LEDs), and the detectors being sili-
con photodiodes, photon multiplier tubes, avalanche photo 
diodes, or CCD cameras. The optical devices using one of 
these sources/detectors can be grouped into three major kinds 
of devices: bed-based imagers, parallel plate imagers, and 
hand-held imagers. The hand-held imagers54,57–94 are capable 
of only reflectance imaging, while parallel and bed-based 
imagers are capable of transillumination and reflectance imag-
ing. Hand-held imagers are generally smaller, less expensive, 
and portable devices which have the benefit of being placed 
easily by a technician. The small device ensures that all 
breast shapes and sizes can be imaged with minimal patient 
discomfort and lack of tissue compression. Bed-based imag-
ers95–105 are a category of imagers which require a subject to 
lie down and suspend the breast tissue to be imaged in special 
imaging bins or enclosures, which facilitate data collection 
and 3D tomographic imaging. Parallel plate imagers106–112 
are similar to bed-based imagers, but instead of relying on 
circular bins, they implement compressive plates similar to 
X-ray mammography systems. This reduces the exclusion of 
subjects by reducing their tissue thickness via compression. 
While the focus of the bed-based and parallel plate imagers 
has been predominantly for 3D tomographic imaging of 
breast cancer, the hand-held optical devices have focused on 
spectroscopic information of the breast at both the diagnostic 
and prognostic stages.
In general, optical breast imaging in the clinic has not 
been systematic, and various research groups have focused 
on technological developments of their devices.56 When 
focusing only on clinically oriented optical mammography 
studies with approximately 2,000 women, it was observed 
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that ∼85% of breast lesions are detectable.56 Additional 
dimensionality to the optical mammography is provided by 
integrating and co-registering the functional information 
of diffuse optical spectroscopy and imaging with X-ray 
mammography and MRI, which provide structural informa-
tion or vascular flow information, respectively. One of the 
goals of the optical breast imaging research community is 
to develop DOI platforms that can be used as stand-alone 
devices or in conjunction with MRI, mammography, or US. 
These platforms would potentially assist in detecting the 
breast cancer disease in mammographically dense tissues, 
distinguishing between malignant and benign lesions, and 
understanding the impact of neoadjuvant chemotherapies. 
More recently, hand-held optical devices are developed 
with a focus on early-stage detection of breast cancer as a 
first-response device.
Optical imaging for breast 
prescreening
Role of optical imaging  
in breast prescreening
Prescreening of the breast typically involves: i) breast self-
examination – a recommendation for all women to become 
familiar with both appearance and feel of their breasts and 
report any changes to their physician; and ii) CBE – an exami-
nation performed by a clinician in which he/she utilizes the 
pads of the fingers to feel the breasts, assessing the shape, 
texture, and the presence of any bumps. Conventionally and 
clinically used screening approaches include mammography, 
US, and MRI,11 as described in the Introduction section. 
Optical imaging is an emerging prescreening or screening 
tool in the area of breast cancer.113
Various research groups have developed hand-held opti-
cal devices (or scanners) for breast cancer imaging,54,57 for 
detection, diagnosis, and/or prognosis. The optical devices 
that focus on early detection (for potential prescreening) of 
breast cancer are tabulated in Table 2 and shown in Figure 2. 
The concept of developing portable, low-cost, hand-held opti-
cal devices for early-stage detection of breast cancer began 
in the late 1990s64 by Tromberg’s research group. Tromberg’s 
device (Device #1) employed laser diodes (of multiple 
wavelengths) and avalanche photodiodes (as detectors) to 
obtain FD-based optical spectroscopic information from 
breast tissues and compare the optical properties of a normal 
breast with that of the benign lesions. Device #1 (Table 1) 
was also used in several studies (for a total of ∼100 subjects) 
to compare healthy and tumor-containing breast tissue.71,72,75 
The results showed differences in the optical properties of the 
tissue based on subject age, tumor size, and tumor pathology. 
The second device (Device #2) developed by researchers 
at University of California Irvine was also based on FD 
diffuse optical spectroscopic imaging using laser diodes 
(at multiple wavelengths) and avalanche photodiodes. Based 
on the measured differences in the absorption coefficients 
between the diseased (ie, tumor) and normal breast tissue, 
the device detected the presence of a lesion in in vivo human 
breast tissue.77–79 The only other FD-based optical device 
(Device #6) was that developed by Zhu and her group at 
University of Connecticut.61,87,114 Unlike other hand-held 
optical devices, Zhu’s device performed multimodal optical 
and US imaging to obtain 3D diffuse optical tomographic 
imaging of the breast. This device imaged the benign and 
malignant breast lesions in human subjects.
Many hand-held optical devices (Devices #3–5, #7–10) 
were based on CW imaging mode. Chance and his group 
developed two portable devices (Devices #3 and #4) of dif-
ferent source–detector configurations and each using LEDs 
as sources and silicon photodiodes as detectors.59,80 Device #3 
was used in an extensive study to show the differences in the 
biochemical and physiological properties of breast tissue con-
taining growing cancers, compared to corresponding normal 
tissue in the contralateral breast.80 In a 6-year study on 116 
patients with 44 confirmed malignancies, they reported the 
ability to distinguish cancerous from noncancerous breast 
tissue with a sensitivity of 96% and specificity of 93%. The 
second device from Chance’s group (Device #4) employed 
two LEDs that were out of phase in order to generate destruc-
tive interference signals.59 The detected signal at the detector 
placed mid-way between the two sources provided a null 
signal, which shifts in the presence of any abnormality. 
This principle was used in detection and 2D localization of 
any breast lesions/abnormalities.59 Another spectroscopic-
based hand-held device (Device #5 in Table 2), which used 
laser diodes as sources, was used to detect breast cancer in 
50 females who have been indicated of suspected breast 
cancer from X-ray mammography.83 The device used in these 
studies (Device #5, P-Scan Imager) was developed by Vioptix 
Inc. as a CW-based NIR spectroscopic device that provides 
real-time 2D mapping of blood oxygen saturation and total 
hemoglobin. From their preliminary studies, the device 
provided 92% diagnostic sensitivity and 67% diagnostic 
specificity in detecting ductal carcinoma.83 Another research 
group from Ohio State University, Xu et al, also used the 
same P-Scan imager (Device #8 in Table 2) for phantom and 
in vivo human subject studies to dynamically characterize 
Breast Cancer: Targets and Therapy 2015:7 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
201
Optical breast prescreening
T
ab
le
 2
 O
pt
ic
al
 im
ag
in
g 
de
vi
ce
s 
de
ve
lo
pe
d 
fo
r 
pr
es
cr
ee
ni
ng
 o
r 
ea
rl
y-
st
ag
e 
br
ea
st
 c
an
ce
r 
im
ag
in
g
N
um
be
r
R
ef
er
en
ce
M
od
al
it
y
M
ea
su
re
m
en
t 
te
ch
ni
qu
e
So
ur
ce
 t
yp
e
D
et
ec
to
r 
ty
pe
Si
ze
C
lin
ic
al
 a
pp
lic
at
io
n(
s)
1
T
ro
m
be
rg
 e
t 
al
64
D
O
S
FD
 (
30
0 
kH
z–
1 
G
H
z)
La
se
r 
di
od
es
 (
10
–3
0 
m
w
) 
(6
74
 n
m
,  
81
1 
nm
, 8
49
 n
m
, 9
56
 n
m
)
A
PD
–
C
om
pa
re
 o
pt
ic
al
 p
ro
pe
rt
ie
s 
of
 n
or
m
al
 a
nd
 
be
ni
gn
 le
si
on
-c
on
ta
in
in
g 
br
ea
st
 t
is
su
e
2
N
o 
et
 a
l79
D
O
S
FD
 (
10
 M
H
z–
1 
G
H
z)
ei
gh
t 
la
se
r 
di
od
es
 (
50
 m
w
)  
(7
83
 n
m
)
A
PD
–
N
on
in
va
si
ve
 b
re
as
t 
ca
nc
er
 d
et
ec
tio
n 
ba
se
d 
on
 fr
eq
ue
nc
y-
do
m
ai
n 
ph
ot
on
 m
ig
ra
tio
n
3
N
io
ka
 a
nd
  
C
ha
nc
e8
0
D
O
S
C
w
Li
gh
t-
em
itt
in
g 
di
od
es
 (
10
–1
5 
m
A
) 
 
(7
60
 n
m
, 8
05
 n
m
, 8
50
 n
m
)
ei
gh
t s
ili
co
n 
di
od
e 
de
te
ct
or
s
∼9
 c
m
 d
ia
m
et
er
D
et
er
m
in
e 
se
ns
iti
vi
ty
 a
nd
 s
pe
ci
fic
ity
 o
f 
de
te
ct
in
g 
br
ea
st
 c
an
ce
r 
in
 1
16
 h
um
an
 
su
bj
ec
ts
. O
bt
ai
ne
d 
93
%
 s
pe
ci
fic
ity
 a
nd
 
96
%
 s
en
si
tiv
ity
4
C
ha
nc
e 
et
 a
l59
D
O
S
C
w
T
w
o 
lig
ht
-e
m
itt
in
g 
di
od
es
 (
20
 m
A
) 
 
(8
00
 n
m
) 
– 
ou
t 
of
 p
ha
se
 s
ou
rc
es
O
ne
 s
ili
co
n 
di
od
e 
de
te
ct
or
9.
3×
6.
5×
3 
cm
3   
(s
im
ila
r 
in
 s
iz
e 
to
  
gl
uc
os
e 
m
et
er
)
D
et
ec
tio
n 
an
d 
2D
 lo
ca
liz
at
io
n 
of
 b
re
as
t 
ca
nc
er
 le
si
on
 in
 a
 h
um
an
 s
ub
je
ct
5
C
he
ng
 e
t 
al
83
D
O
S
C
w
La
se
r 
di
od
es
 (
0.
15
 w
/c
m
2 )
  
(6
90
 n
m
, 8
30
 n
m
)
PM
T
5.
5×
5.
5×
10
.2
 c
m
3
D
et
er
m
in
e 
se
ns
iti
vi
ty
 a
nd
 s
pe
ci
fic
ity
 o
f 
de
te
ct
in
g 
du
ct
al
 c
ar
ci
no
m
a 
in
 5
0 
hu
m
an
 
su
bj
ec
ts
. O
bt
ai
ne
d 
92
%
 d
ia
gn
os
ed
 
se
ns
iti
vi
ty
 a
nd
 6
7%
 d
ia
gn
os
ed
 s
pe
ci
fic
ity
6
Z
hu
 e
t 
al
11
4
D
O
T
 a
nd
 U
S
FD
 (
20
0 
M
H
z)
ei
gh
t 
du
al
-w
av
el
en
gt
h 
la
se
r 
di
od
es
  
(6
90
 n
m
, 7
80
 n
m
, 8
30
 n
m
)
A
PD
–
im
ag
e 
be
ni
gn
 a
nd
 m
al
ig
na
nt
 le
si
on
s 
at
 e
ar
ly
 
st
ag
e 
in
 b
re
as
t 
tis
su
e
7
Fl
ex
m
an
 e
t 
al
11
5
D
O
S 
(w
ir
el
es
s)
C
w
La
se
r 
di
od
es
 (
10
 m
w
) 
(7
80
 n
m
,  
80
8 
nm
, 8
50
 n
m
, 9
04
 n
m
)
T
w
o 
si
lic
on
 
ph
ot
od
io
de
s
11
.5
×1
6×
2.
5 
cm
3
Li
qu
id
 p
ha
nt
om
 s
tu
di
es
 t
o 
de
m
on
st
ra
te
 
m
ea
su
re
m
en
t 
of
 H
bO
, H
bR
, a
nd
 s
ca
tt
er
in
g 
in
 t
is
su
es
. i
n 
vi
vo
 d
at
a 
no
t 
av
ai
la
bl
e
8
X
u 
et
 a
l60
D
O
i (
P-
Sc
an
 im
ag
er
, 
v
io
pt
ix
 in
c.
)
C
w
ei
gh
t 
du
al
-w
av
el
en
gt
h 
la
se
r 
 
di
od
es
 (
69
0 
nm
, 8
30
 n
m
)
ei
gh
t 
si
lic
on
 
ph
ot
od
io
de
s
5.
5×
5.
5×
10
.2
 c
m
3
in
 v
iv
o 
hu
m
an
 t
is
su
e 
st
ud
ie
s 
fo
r 
dy
na
m
ic
 
ch
ar
ac
te
ri
za
tio
n 
by
 r
ec
on
st
ru
ct
in
g 
ab
so
rp
tio
n 
co
ef
fic
ie
nt
s.
 In
 v
iv
o 
br
ea
st
 
im
ag
in
g 
st
ud
ie
s 
ar
e 
no
t 
av
ai
la
bl
e
9
La
bi
b 
et
 a
l11
6
Br
ea
st
 il
lu
m
in
at
io
n
C
w
61
7 
nm
 v
is
ib
le
 r
ed
 li
gh
t
N
ak
ed
 e
ye
–
im
ag
ed
 3
10
 w
om
en
 (
43
.6
±1
2.
4 
ye
ar
s)
 
fo
r 
br
ea
st
 s
cr
ee
ni
ng
. O
bt
ai
ne
d 
73
.7
%
 
sp
ec
ifi
ci
ty
, 9
3%
 s
en
si
tiv
ity
, 9
1.
4%
 P
Pv
, 
77
.8
%
 N
Pv
, a
nd
 8
8.
2%
 a
cc
ur
ac
y.
 D
et
ec
ts
 
le
si
on
s 
15
 m
m
 a
nd
 a
bo
ve
10
R
od
ri
gu
ez
 e
t 
al
11
7
D
O
i (
N
iR
O
S)
C
w
Li
gh
t-
em
itt
in
g 
di
od
e 
 
(7
10
 n
m
)
C
M
O
S 
ca
m
er
a
5×
7×
15
 c
m
3
in
 v
iv
o 
br
ea
st
 im
ag
in
g 
st
ud
ie
s 
us
in
g 
tu
m
or
-
lik
e 
ta
rg
et
s.
 N
o 
da
ta
 fr
om
 b
re
as
t 
ca
nc
er
 
su
bj
ec
ts
A
bb
re
vi
at
io
ns
: A
PD
, a
va
la
nc
he
 p
ho
to
di
od
e;
 C
M
O
S,
 c
om
pl
em
en
ta
ry
 m
et
al
 o
xi
de
 s
em
ic
on
du
ct
or
; C
w
, c
on
tin
uo
us
 w
av
e;
 D
O
i, 
di
ffu
se
 o
pt
ic
al
 im
ag
in
g;
 D
O
S,
 d
iff
us
e 
op
tic
al
 s
pe
ct
ro
sc
op
y;
 D
O
T
, d
iff
us
e 
op
tic
al
 to
m
og
ra
ph
y;
 F
D
, f
re
qu
en
cy
 
do
m
ai
n;
 N
iR
O
S,
 n
ea
r-
in
fr
ar
ed
 o
pt
ic
al
 s
ca
nn
er
; P
M
T
, p
ho
to
n 
m
ul
tip
lie
r 
tu
be
; P
Pv
, P
os
iti
ve
 p
re
di
ct
iv
e 
va
lu
e;
 N
Pv
, N
eg
at
iv
e 
pr
ed
ic
tiv
e 
va
lu
e;
 U
S,
 u
ltr
as
ou
nd
.
Breast Cancer: Targets and Therapy 2015:7submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
202
Godavarty et al
the tissue in response to dynamic compression stimuli.60 
The device demonstrated that it can detect tissue optical, 
mechanical, and physiological changes under the dynamic 
loading condition, although requiring further evaluation for 
breast cancer studies. One of the latest devices employing 
laser diodes as sources was made wireless.115 However, to 
date, only liquid phantom studies using Device #7 were 
performed to demonstrate the measurements of HbO, HbR, 
and scattering properties of the tissue.
On the contrary to the NIR-based hand-held devices, a 
breast illuminator employed visible red light (617 nm wave-
length) to transmit the breast tissues and visualize the optical 
contrast using the naked eye.116 In a study at the National 
Cancer Institute at Cairo University, BreastLight (Device #9) 
was employed on 310 women, and the results were compared 
to X-ray mammography and histopathology (when suspicious 
cases were found in mammography). Breast illumination 
using BreastLight device and X-ray mammography were 
concordant in 277/310 cases (89.4%). The breast illumination 
device provided a sensitivity of 93%, specificity of 73.7%, a 
positive predictive value of 91.4%, and a negative predictive 
value of 77.8%, demonstrating the device as a potential breast 
cancer prescreening tool.
At our Optical Imaging Laboratory at Florida Interna-
tional University, a portable hand-held wide-field NIR optical 
scanner (NIROS) (Device #10) was developed for DOI of 
breast tissues via transillumination mode of imaging.117 The 
details of this device and the preliminary in vivo studies are 
described in the following section.
Our ongoing efforts in breast 
prescreening using optical imaging
Most of the hand-held optical imagers available to date, 
whether for prescreening/screening or diagnostic/prognostic 
applications, employ optical fibers to illuminate/detect NIR 
signals. The use of optical fibers allows precise launching 
and collection of NIR optical signals at point locations on 
the tissue surface. The intensity and location of these source 
and detector points using optical fibers when measured allow 
3D tomographic imaging. However, the use of optical fibers 
can also be disadvantageous. Many optical fibers or fiber 
bundles are required to enhance the spatial resolution of 
A E H
B
C
D
F
G
I
Device #1 Devices #5, #8
Device #2
Device #6
Device #10
CMOS
cameraDevice #3
Device #4
Device #7
Sources
Detectors
Ultrasound
Transillumination source
Device #9
Figure 2 Different hand-held probes developed for early detection of breast cancer, showing their source–detector layouts and the actual device.
Note: The source-detector configuration and the actual device are shown for each of the devices (A-I) in Table 2. (A) Adapted from Tromberg BJ. Optical scanning and breast 
cancer. Acad Radiol. 2005;12(8):923–924, with permission from elsevier.62 (B) ©2005 ieee. Reprinted, with permission, from No KS, Chou PH. Mini-FDPM and heterodyne 
mini-FDPM: handheld non-invasive breast cancer detectors based on frequency-domain photon migration. IEEE Trans Circ Syst I Reg Papers. 2005;52(12):2672–2685.77 
(C) Adapted from Chance B, Nioka S, Zhang J, et al. Breast cancer detection based on incremental biochemical and physiological properties of breast cancers: a six-year, 
two-site study. Acad Radiol. 2005;12(8):925–933, with permission from elsevier.138 (D) Adapted with permission from Chance B, Zhao Z, wen S, Chen Y. Simple ac circuit for 
breast cancer detection and object detection. Rev Sci Instrum. 2006;77:064301. Copyright ©2006, AiP Publishing LLC.59 (E) Adapted with permission from Xu RX, Qiang B, 
Mao JJ, Povoski SP. Development of a handheld near-infrared imager for dynamic characterization of in vivo biological tissue systems. Appl Opt. 2007;46(30):7442–7451.59 
(F) Adapted from Zhu Q, Huang M, Chen N, et al. Ultrasound-guided optical tomographic imaging of malignant and benign breast lesions: initial clinical results of 19 cases. 
Neoplasia. 2003;5(5):379–388, with permission from elsevier.114 (G) Adapted from Flexman ML, Kim HK, Stoll R, Khalil MA, Fong CJ, Heilscher AH. A wireless handheld probe 
with spectrally constrained evolution strategies for diffuse optical imaging of tissue. Rev Sci Instrum. 2012;83:033108. Copyright ©2012, AiP Publishing LLC.115
Abbreviation: CMOS, complementary metal oxide semiconductor.
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the imaging system, but at the cost of increased bulkiness, 
reduced flexibility (especially in hand-held devices), and 
instrumentation expense. In recent years, a few research 
groups have developed fiber-free NIR imaging systems using 
wide-field detectors (eg, CCD or complementary metal oxide 
semiconductor [CMOS] camera) for noncontact imaging.118–137 
These imagers employ either reflectance or transmittance 
mode to image tissue phantoms, blood vessels, and/or veins of 
the skin surface. Unlike the fiber-based devices (with contact) 
that can image deep tissues as in breast imaging, the fiber-free 
noncontact optical devices developed to date have been used 
for sub-surface imaging (#1 cm deep).
In our Optical Imaging Laboratory, a fiber-free hand-
held NIROS has been developed toward deep tissue imaging 
(.1 cm target depth) in both reflectance and transmittance 
mode. Preliminary in vivo breast imaging studies using 
the scanner as a noncontact device were performed to deter-
mine its deep target detectability and its potential applicabil-
ity as a breast cancer prescreening tool.
instrumentation
The fiber-free noncontact hand-held NIROS comprises a 
hand-held probe (Figure 2, Device #10), a controller box, 
and a computer with custom-developed image acquisition/
processing toolbox. The hand-held probe (weighing ,1 lb) 
consists of a 710 nm LED source light for area illumination 
and an NIR-sensitive CMOS camera for area detection. The 
LED source encased in a heat sink is driven by an LED 
driver (placed in the controller box) that controls the radiat-
ing power of the source. The LED driver and the CMOS 
camera are synchronized in the data acquisition timing via 
a microcontroller unit, and both the source and detector are 
powered by the computer’s USB port. The diffuse reflected/
transilluminated NIR signals from the tissue surface are 
detected by the camera after the signals have been filtered 
using a 645-nm long-pass optical filter and focused using an 
8.5 mm focusing lens. A MATLAB-based imaging software 
was developed in order to automate the data acquisition, data 
storage, and data processing. For the breast imaging studies, 
two transparent parallel acrylic plates were used to hold the 
breast tissue during transillumination-based imaging using 
NIROS (Figure 3).
in vivo breast imaging  
studies using NiROS
The Florida International University IRB-approved studies 
imaged ten healthy female subjects over the age of 21 years 
with no known history of breast cancer. The breast imaging 
studies were performed with the breast tissue placed in 
between the two transparent plates to provide for transmission 
imaging mode. As seen in Figure 3, the top plate is adjustable 
in order to perform studies with or without applied pressure 
and to accommodate different breast tissue sizes. The detector 
is placed above the top plate, and the LED source is placed 
beneath the bottom fixed plate. A 0.46 cm3 target was filled 
with a solution of 0.8% India ink in Liposyn in order to cre-
ate a tumor-like agent with high-absorption properties. The 
target was positioned beneath the breast tissue and above 
the bottom plate and moved to different locations (noted by 
clock positions) throughout the study.
The goal of the studies was to qualitatively determine 
the ability of NIROS to detect the targets when both the 
applied pressure and target locations were varied. Images 
were acquired with and without pressure by adjusting the 
top moveable plate and also by moving the target to vari-
ous clock locations in order to assess NIROS’s capacity to 
determine where the targets were placed. The studies were 
performed in transmission mode with the source below the 
tissue and the detector above the breast tissue. The images 
were acquired without external light; only the laptop was on 
with the screen brightness at the minimum setting, in order to 
minimize noise. The power of the LED was measured several 
times throughout the study, and the CMOS exposure time was 
adjusted for each subject as well as the focus.
Image processing was carried out using a custom-
developed MATLAB-based software. The first step was to 
Moveable plate
Fixed plate
NIR
Detector
Breast tissue
Source
Target
Figure 3 Setup for breast imaging studies consisting of the breast tissue placed in 
between two transparent plates.
Notes: A detector is placed above the top plate, the source is placed beneath the 
bottom plate, and a target is placed beneath the breast tissue and above the bottom 
plate.
Abbreviation: NiR, near-infrared.
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co-register the raw NIR images, so that the two images are 
aligned on the same coordinate system. This was followed 
by subtraction of the NIR image of the breast tissue obtained 
without the target from the NIR image obtained with the 
target present. The regions outside the breast tissue were 
masked (or cropped) in order to improve the image contrast 
by removing the noise. Finally, minimum and maximum pixel 
values were set by the user in order to distinguish areas of 
increased or decreased absorption in the image, allowing 
for the recognition of the target with improved contrast. The 
targets were seen as areas with increased absorption.
Experimental results from two different subjects are shown 
below in Figures 4 and 5. Figure 4 shows a set of images from 
subject #1’s left breast at a constant pressure. Figure 4B has 
the target, and Figure 4A does not have a target. Figure 4C is 
the final image after data processing including co-registration, 
subtraction, and masking. The region of increased absorption 
in the final image reveals where the target was placed.
Figure 5 also shows a set of images from subject #2 with 
applied pressure and with the target in the 6 o’clock location. 
The target can be distinguished in the last picture (Figure 5C) 
as the region in green in the bottom portion of the breast. 
It was also noticed that when the target was placed furthest 
away from the source, as in Figure 5, the target was still 
detectable due to its higher absorption. The greatest distance 
between the target and the top plate at which a target was able 
to be detected was at 8.8 cm. Hence, while the raw images 
do not reveal information about the location of the target, the 
target’s location can indeed be seen in the final image once 
image processing has been performed.
The preliminary in vivo studies on the normal breast tis-
sues with a superficially placed target in the intramammary 
fold have shown that an increased absorption was clearly 
observed from the target site (up to 8.8 cm deep) when 
(maximum comfortable) pressure was applied. To date, 
an area illumination and area detection-based NIR device 
have demonstrated only sub-surface imaging (1 cm or less). 
NIROS has demonstrated detection of deep targets using area 
illumination/detection approach, along with post-processing 
techniques to improve the target detection greater than 8 cm 
deep. Although the images cannot precisely locate the target 
in 2D, their detected location was close to the true clock 
location as seen in Figures 4 and 5.
In an actual breast cancer case, NIROS may translate to 
imaging the contralateral breast and comparing the differences 
in the absorption across the two tissues, via symmetric clock-
wise imaging of the breast (as in an US approach). Currently, 
work is carried out to image both the left and right breast tis-
sues and compare the two, as there are structural differences 
between the two. These structural differences can lead to differ-
ences in NIR images (from physiological differences). Hence, 
understanding the hemodynamic differences between normal 
left and right breasts can help differentiate between the breast 
abnormalities with respect to the contralateral breast (acting as 
a reference) in the future. There are ongoing efforts to perform 
extensive in vivo studies under various experimental condi-
tions to determine the capabilities of the noncontact hand-held 
NIROS in detecting smaller and deeper targets.
Studies in the past have revealed that only half of the 
insured women over the age of 40 are claiming annual 
mammogram screenings, despite medical recommendations 
endorsed across the USA and the world. Reasons for noncom-
pliance suggested from various studies include discomfort 
during the exam, concern over radiation exposure, access 
to facilities, inconvenience/lack of time, embarrassment/
cultural barriers, and denial. Thus, to improve breast cancer 
screening compliance, a need exists for a safe, comfortable, 
accessible, and convenient breast cancer prescreening tool 
to better triage the subjects for early detections/treatment 
options. There is a potential for a functional imaging tool 
A B C
60
40
20
0
−20
−40
−60
Figure 4 Transmitted NiR optical images of the left breast from subject #1 that were captured at a constant pressure applied on the breast (in all images).
Notes: (A) NiR image was captured without pressure and without target. (B) NiR image was captured without pressure and with the target placed at the location indicated 
by the black hollow circle at 12 o’clock. (C) Post-processed NiR image after co-registering, subtracting, and masking. The black hollow circle in (B and C) depicts the 2D 
location of the target at 12 o’clock position in the intramammary fold of the left breast.
Abbreviation: NiR, near-infrared.
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to provide additional information to the CBE or SBEs at 
the prescreening stage that may provide more informa-
tion to the clinicians. Although the hand-held noncontact 
NIROS cannot determine the accurate location of a target, 
as other 3D tomography-based optical imagers, it may have 
the potential to detect the presence of any abnormalities 
(or target(s)) as an initial assessment to breast prescreening. 
The ability to perform deep tissue imaging using a portable 
hand-held NIROS allows for in vivo breast studies. Following 
the extensive in vivo studies on normal subjects, studies 
will be performed on breast cancer subjects to validate the 
above-stated hypothesis and determine the capabilities of the 
device for breast cancer prescreening. In this effort, NIROS 
is currently modified to allow hemodynamic imaging (using 
a dual-wavelength source system) such that the changes 
in oxy- and deoxy-hemoglobin from breast tissues can be 
determined apart from changes in absorption alone.
Conclusion
In this review, the existing and clinically applied breast can-
cer prescreening tools and screening imaging modalities are 
described. With a need for a systematic prescreening or early 
detection of breast cancer, the application of optical imaging 
modality is described. Although various research groups have 
developed many optical imaging devices for detection, diag-
nosis, and prognosis of breast cancer, a few of these devices 
have focused on early detection or prescreening. While a few 
of these hand-held optical devices have performed in vivo 
clinical studies on breast cancer subjects, there still remains 
extensive work to be performed to assess optical devices as 
potential future breast prescreening devices.
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